File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
  • Basic View
  • Metadata View
  • XML View
TitleHigh expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
 
AuthorsHe, LR1 1
Liu, MZ1 1
Li, BK1
Jia, WH1
Zhang, Y1
Liao, YJ1
Chen, YC2
Zhang, LJ1
Guan, XY1
Zeng, YX1
Kung, HF1 2
Xie, D1
 
KeywordsChemoradiotherapy
Esophageal squamous cell carcinoma
EZH2
Immunohistochemistry
Prognosis
 
Issue Date2010
 
PublisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
CitationInternational Journal Of Cancer, 2010, v. 127 n. 1, p. 137-147 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.25031
 
AbstractThe enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in-situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p < 0.001) and lack of clinical complete response to CRT (p 5 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis-free survival (MFS) (p = 0.003), poor progression-free survival (PFS) (p = 0.001) and poor disease-specific survival (DSS) (p < 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC. © 2009 UICC.
 
ISSN0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
DOIhttp://dx.doi.org/10.1002/ijc.25031
 
ISI Accession Number IDWOS:000278148800015
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

Grant sponsor: Major State Basic Research Program of China; Grant number: 2006CB910104; Grant sponsor: the 863 Project of China; Grant number: 2007AA021901

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHe, LR
 
dc.contributor.authorLiu, MZ
 
dc.contributor.authorLi, BK
 
dc.contributor.authorJia, WH
 
dc.contributor.authorZhang, Y
 
dc.contributor.authorLiao, YJ
 
dc.contributor.authorChen, YC
 
dc.contributor.authorZhang, LJ
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorKung, HF
 
dc.contributor.authorXie, D
 
dc.date.accessioned2010-10-31T10:39:14Z
 
dc.date.available2010-10-31T10:39:14Z
 
dc.date.issued2010
 
dc.description.abstractThe enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in-situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p < 0.001) and lack of clinical complete response to CRT (p 5 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis-free survival (MFS) (p = 0.003), poor progression-free survival (PFS) (p = 0.001) and poor disease-specific survival (DSS) (p < 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC. © 2009 UICC.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationInternational Journal Of Cancer, 2010, v. 127 n. 1, p. 137-147 [How to Cite?]
DOI: http://dx.doi.org/10.1002/ijc.25031
 
dc.identifier.doihttp://dx.doi.org/10.1002/ijc.25031
 
dc.identifier.epage147
 
dc.identifier.hkuros175308
 
dc.identifier.isiWOS:000278148800015
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
863 Project of China2007AA021901
Funding Information:

Grant sponsor: Major State Basic Research Program of China; Grant number: 2006CB910104; Grant sponsor: the 863 Project of China; Grant number: 2007AA021901

 
dc.identifier.issn0020-7136
2012 Impact Factor: 6.198
2012 SCImago Journal Rankings: 2.309
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid19904743
 
dc.identifier.scopuseid_2-s2.0-77953444201
 
dc.identifier.spage137
 
dc.identifier.urihttp://hdl.handle.net/10722/124523
 
dc.identifier.volume127
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home
 
dc.publisher.placeUnited States
 
dc.relation.ispartofInternational Journal of Cancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsInternational Journal of Cancer. Copyright © John Wiley & Sons, Inc..
 
dc.rightsThis is a preprint of an article published in International Journal of Cancer, 2010, v. 127 n. 1, p. 138-147
 
dc.subject.meshEsophageal squamous cell carcinoma
 
dc.subject.meshEZH2
 
dc.subject.meshChemoradiotherapy
 
dc.subject.meshPrognosis
 
dc.subject.meshImmunohistochemistry
 
dc.subjectChemoradiotherapy
 
dc.subjectEsophageal squamous cell carcinoma
 
dc.subjectEZH2
 
dc.subjectImmunohistochemistry
 
dc.subjectPrognosis
 
dc.titleHigh expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>He, LR</contributor.author>
<contributor.author>Liu, MZ</contributor.author>
<contributor.author>Li, BK</contributor.author>
<contributor.author>Jia, WH</contributor.author>
<contributor.author>Zhang, Y</contributor.author>
<contributor.author>Liao, YJ</contributor.author>
<contributor.author>Chen, YC</contributor.author>
<contributor.author>Zhang, LJ</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2010-10-31T10:39:14Z</date.accessioned>
<date.available>2010-10-31T10:39:14Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>International Journal Of Cancer, 2010, v. 127 n. 1, p. 137-147</identifier.citation>
<identifier.issn>0020-7136</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/124523</identifier.uri>
<description.abstract>The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinoma (ESCC) are unclear. In this study, the methods of immunohistochemistry and fluorescence in-situ hybridization were used to examine protein expression and amplification of EZH2 in 98 pretreatment biopsy specimens of ESCC who received definitive chemoradiotherapy (CRT). High expression of EZH2 and amplification of EZH2 was found in 54.1% and 12.0% of ESCCs, respectively. High EZH2 expression was significantly correlated with increased cell proliferation (p = 0.009), high histopathological grade (p = 0.002), regional (p = 0.025) and distant lymph node metastasis (p &lt; 0.001) and lack of clinical complete response to CRT (p 5 0.028). Univariate analysis revealed that high expression of EZH2 was associated with poor metastasis-free survival (MFS) (p = 0.003), poor progression-free survival (PFS) (p = 0.001) and poor disease-specific survival (DSS) (p &lt; 0.001). In multivariate analysis, high expression of EZH2, together with lack of clinical complete response, were evaluated as significant independent prognostic factors of MFS, PFS and DSS for patients with ESCC. These findings suggest that high expression of EZH2 correlates with tumor aggressiveness and adverse patient outcome in ESCC treated with definitive CRT. Evaluation of EZH2 expressions might be useful for predicting tumor response to CRT and prognosis for patients with ESCC. &#169; 2009 UICC.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc.. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/journal/29331/home</publisher>
<relation.ispartof>International Journal of Cancer</relation.ispartof>
<rights>International Journal of Cancer. Copyright &#169; John Wiley &amp; Sons, Inc..</rights>
<rights>This is a preprint of an article published in International Journal of Cancer, 2010, v. 127 n. 1, p. 138-147</rights>
<subject>Chemoradiotherapy</subject>
<subject>Esophageal squamous cell carcinoma</subject>
<subject>EZH2</subject>
<subject>Immunohistochemistry</subject>
<subject>Prognosis</subject>
<subject.mesh>Esophageal squamous cell carcinoma</subject.mesh>
<subject.mesh>EZH2</subject.mesh>
<subject.mesh>Chemoradiotherapy</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Immunohistochemistry</subject.mesh>
<title>High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0020-7136&amp;volume=127&amp;issue=1&amp;spage=138&amp;epage=147&amp;date=2010&amp;atitle=High+expression+of+EZH2+is+associated+with+tumor+aggressiveness+and+poor+prognosis+in+patients+with+esophageal+squamous+cell+carcinoma+treated+with+definitive+chemoradiotherapy</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/ijc.25031</identifier.doi>
<identifier.pmid>19904743</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77953444201</identifier.scopus>
<identifier.hkuros>175308</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77953444201&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>127</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>137</identifier.spage>
<identifier.epage>147</identifier.epage>
<identifier.isi>WOS:000278148800015</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Sun Yat-Sen University
  2. Chinese University of Hong Kong